Ataxin-1 Antibodies

Santa Cruz Biotechnology features a diverse variety of Ataxin-1 monoclonal antibodies for research in understanding Ataxin-1's role in various cellular processes. The monoclonal antibodies are validated for western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). Ataxin-1 plays a critical role in the regulation of gene expression and is implicated in the pathogenesis of spinocerebellar ataxia type 1 (SCA1), a neurodegenerative disorder. Understanding Ataxin-1 function is essential for elucidating the molecular mechanisms underlying SCA1 and developing potential therapeutic strategies. Research on Ataxin-1 provides valuable insights into protein aggregation and neurodegeneration. Investigating Ataxin-1's molecular interactions helps reveal its role in both normal cellular function and disease states. Current research focuses on understanding how Ataxin-1 mutations lead to neurodegeneration and identifying potential therapeutic targets. Exploring Ataxin-1's involvement in transcriptional regulation continues to yield important discoveries about gene expression control mechanisms. Santa Cruz Biotechnology monoclonal antibodies support researchers worldwide in advancing scientific understanding of neurodegenerative diseases and potential treatments.